1. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice.
- Author
-
Zapata-Pérez, Rubén, Tammaro, Alessandra, Schomakers, Bauke V., Scantlebery, Angelique M. L., Denis, Simone, Elfrink, Hyung L., Giroud-Gerbetant, Judith, Cantó, Carles, López-Leonardo, Carmen, McIntyre, Rebecca L., van Weeghel, Michel, Sánchez-Ferrer, Álvaro, and Houtkooper, Riekelt H.
- Abstract
Nicotinamide adenine dinucleotide (NAD+) homeostasis is constantly compromised due to degradation by NAD+-dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF